IN THE CLINIC
NEW & ONGOING STUDIES
The Clinic is the last step in the MMRF Precision Medicine Model and aims to accelerate clinical
trials to rapidly bring new treatments to patients. The Multiple Myeloma Research Consortium
(MMRC), a unique collaborative model of 25 centers in the United States and Canada, evaluates
novel agents and combinations for their safety, efficacy, and feasibility in Phase 1 & 2 clinical trials.
To date, the MMRC has conducted 76 clinical trials, 24 of which are currently ongoing.
2017 ACTIVE CLINICAL TRIALS
NOVEL AGENTS/MECHANISMS
RELAPSED
OR R/RACE011
ANTIBODIES & IMMUNE
PIS & IMIDS
MOLECULARLY TARGETED
ACE011 Isatuximab/Kyprolis Pomalyst/Kyprolis/Dex Idasanutline/
Ixa 17p deleted
Ibrutinib/Kyprolis Empliciti/Pomalyst/Dex Pomalyst/Ninlaro/
EMD/PCL PINR Biomarker-driven
Ruxolitinib/Kyprolis
(Car-Jak) Rev/Dex/Empliciti +/-
Cyclophos (Amyloidosis) Dabrafenib/Trametinib
Venetoclax/Ninlaro Empliciti/Pomalyst/
Velcade/Dex JNJ-42756493
Selinexor/Dex Isatuximab
Selinexor/Kyprolis
NEW DX./
TRANSPLANT
Empliciti/Rev/
Velcade/Dex
Ixazomib/Revlimid/
Dex Transplant*
Empliciti/Rev/Dex
SMM
KEY
Empliciti/Kyprolis/
Rev/Dex
Phase 1
Phase 1/2
Phase 2
*There are two similar but distinct studies led by Washington University and the University of Chicago.
Question about clinical trials? Please call our patient support center at 1.866.603.6628
To search for clinical trials, visit TheMMRF.org/TrialFinder
8
T H E M M R F.ORG